Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Thermo Fisher Scientific Inc. (TMO)

NYQ · Diagnostics & Research

$576.41+16.88 (+3.02%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$214.21B
P/E (TTM)
30.12
EPS
$19.14
Div Yield
0.34%
52W Range
$435.27–$643.99
Beta
0.87

Company overview

Next earnings: 2026-10-21(85d)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Peers in Diagnostics & Research

All in industry →

Recent press releases

April 2026

3 months ago8-KHealthcare

Thermo Fisher Reports Q1 2026 Earnings, Acquires Clario for $8.8B

TMOTHERMO FISHER SCIENTIFIC INC.

# 🧾 What This Document Is This is an **earnings release** for Thermo Fisher Scientific's first quarter of 2026. It's like a report card that the company sends to the public and the SEC to show how it performed financially. It contains the official numbers, a summary from the CEO, and details on the

Read summaryView on SEC EDGAR
3 months agoARSHealthcare

TMO Posts $43.8B Revenue and 23% Margin in 2025 ARS

TMOTHERMO FISHER SCIENTIFIC INC.

# 🔎 What This Document Is This is Thermo Fisher Scientific's **Annual Report to Shareholders (ARS)** for the year 2025. Think of it as the company's "yearbook" or highlight reel. Unlike the dense, legalistic 10-K filing, the ARS is a more narrative and visual report designed for investors, explain

Read summaryView on SEC EDGAR
3 months agoDEF 14AHealthcare

THERMO FISHER SCIENTIFIC INC. — DEF 14A Filing

TMOTHERMO FISHER SCIENTIFIC INC.

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)**. Think of it as the official "meeting agenda" and "information packet" that a public company sends to its shareholders before an annual meeting. 👉 **Why it exists:** To give shareholders the information they need to vot

Read summaryView on SEC EDGAR
3 recent filings shown in the timeline above. View all SEC filings →

Thermo Fisher Scientific Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
30,677,885 sh+3.5%
34,133,702 sh+0.8%
FMR LLC$5.67B
9,793,347 sh+29.0%
16,613,761 sh+1.4%
11,003,814 sh+7.0%
5,945,838 sh+9.3%
2,644,808 sh+205.1%

People at Thermo Fisher Scientific Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$1.72B
NI —
06/25
$1.79B
NI $1.62B
09/25
$11.12B
NI $1.62B
RevenueNI = Net Income
EPS trend (diluted)
Latest: $4.27
Prior: $4.28
Revenue sparkline